Pulmonary delivery of pharmaceuticals

Details Pulmonary delivery of pharmaceuticals Pulmonary delivery of pharmaceuticals

1998-05-01

2000-05-09

Bawa, Raj

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

424 46, 514826, A61K 912

Patent

active

060600691

ABSTRACT:
In a method for treating lung diseases, a drug formulation is prepared by combining micronized crystalline beclomethasone dipropionate and lactose. The drug formulation is placed into a dry powder inhaler which provides inhalable drug particles having a mass median diameter of about 0.5-5.8 microns. The inhaler is preferably largely flow rate independent. Drug and lactose particles are separated in the inhaler during inhalation, most desirably via a spinning element. Due to deep deposition, the drug particles persist in the lungs for a surprisingly long duration, increasing the therapeutic effect of each dose. The patient inhales the drug particles with an inspiratory flow rate of about 10-60 liters/minute, to produce a deep lung deposition of inhaled particles.

REFERENCES:
patent: 5225183 (1993-07-01), Purewal et al.
patent: 5674471 (1997-10-01), Akehurst et al.
Moren, F. (1993) Aerosols in Medicine: Principle, Diagnosis and Theraby, Chapter 13, pages 321-350. Elsevier Science Publishers, Netherlands.

Affiliated with

Also associated with

Rating

Pulmonary delivery of pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pulmonary delivery of pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pulmonary delivery of pharmaceuticals will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1062228